Merus (NASDAQ:MRUS) Given a $110.00 Price Target by BMO Capital Markets Analysts

Merus (NASDAQ:MRUS - Get Free Report) has been assigned a $110.00 price target by equities research analysts at BMO Capital Markets in a report issued on Friday, MarketBeat Ratings reports. The brokerage presently has an "outperform" rating on the biotechnology company's stock. BMO Capital Markets' price objective would indicate a potential upside of 116.00% from the stock's previous close.

Several other research firms have also weighed in on MRUS. Wells Fargo & Company lowered their price objective on Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. Piper Sandler started coverage on Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 price target on shares of Merus in a report on Monday, May 19th. Finally, Guggenheim reiterated a "buy" rating and issued a $109.00 price objective on shares of Merus in a research report on Friday, March 28th. Fourteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $86.00.

Merus Price Performance

MRUS traded up $0.13 on Friday, hitting $50.93. The company had a trading volume of 800,740 shares, compared to its average volume of 741,837. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -12.90 and a beta of 0.94. Merus has a 1-year low of $33.19 and a 1-year high of $61.28. The company's fifty day moving average price is $42.93 and its 200 day moving average price is $43.47.

Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, sell-side analysts forecast that Merus will post -3.85 EPS for the current year.

Institutional Investors Weigh In On Merus

A number of institutional investors and hedge funds have recently modified their holdings of MRUS. Boxer Capital Management LLC acquired a new stake in Merus during the 4th quarter worth $79,895,000. Paradigm Biocapital Advisors LP boosted its holdings in Merus by 99.4% during the first quarter. Paradigm Biocapital Advisors LP now owns 3,369,699 shares of the biotechnology company's stock worth $141,831,000 after buying an additional 1,679,777 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Merus by 34.9% during the 1st quarter. Wellington Management Group LLP now owns 4,718,172 shares of the biotechnology company's stock worth $198,588,000 after buying an additional 1,220,519 shares during the period. Avoro Capital Advisors LLC raised its position in shares of Merus by 56.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock valued at $89,356,000 after acquiring an additional 770,000 shares during the period. Finally, Westfield Capital Management Co. LP boosted its stake in Merus by 51.2% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,501,220 shares of the biotechnology company's stock worth $63,186,000 after acquiring an additional 508,063 shares during the last quarter. 96.14% of the stock is owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.